AI Expert Exscientia Adds BMS To Big Pharma Client List
$50m Upfront, Potential Value Of Pact Is Over $1.2bn
Executive Summary
BMS is impressed with Exscientia's projects with recently acquired Celgene and has signed up to use the UK firm's artificial intelligence platform to accelerate the discovery of small molecules in areas including oncology and immunology.
You may also be interested in...
The Inexorable Rise Of Exscientia
The UK firm has not completed a clinical trial yet but having raised over $350m from its NASDAQ initial public offering and an extra $160m from a private placement, Exscientia's future looks extremely bright.
Digital Events, Social Media Move Up Pharma’s Marketing Playbook
Pharma is switching up its digital marketing playbook to map multiple touch points, including digital congresses and social media chats to deliver not just a product but a better customer experience, executives from Pfizer, Novo Nordisk and ViiV Healthcare say.
BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate
Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.